The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than
aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
Phase:
N/A
Details
Lead Sponsor:
University of Cambridge
Collaborators:
Cambridge University Hospitals NHS Foundation Trust Institute of Cancer Research, United Kingdom